Pilot study of a randomised controlled trial of antenatal thromboprophylaxis
Completed
- Conditions
- Pregnancy and childbirth: thromboembolic disease (TED)Pregnancy and ChildbirthThromboembolic disease (TED)
- Registration Number
- ISRCTN21644138
- Lead Sponsor
- HS R&D Regional Programme Register - Department of Health (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 16
Inclusion Criteria
Pregnant women who are at risk of developing thromboembolic disease (TED)
Exclusion Criteria
1. Women are known to have a thrombophillia sensitivity
2. Have had more than one previous episode of TED
3. Are known to have heparin sensitivity
4. Have had a previous cerebral venous thrombosis
5. Are receiving long term anticoagulant therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie antenatal thromboprophylaxis efficacy in preventing thromboembolic disease during pregnancy?
How does antenatal thromboprophylaxis compare to standard-of-care treatments like low molecular weight heparin for TED in high-risk pregnancies?
Which biomarkers correlate with response to thromboprophylaxis in pregnant patients with inherited thrombophilia or Factor V Leiden mutations?
What are the safety profiles and management strategies for bleeding risks in ISRCTN21644138 antenatal thromboprophylaxis trials?
Are combination therapies involving anticoagulants and antiplatelet agents more effective than monotherapy for TED prevention in pregnancy?